This study will evaluate the safety, tolerability, and anti-tumor activity of amivantamab SC as monotherapy and in addition to pembrolizumab or paclitaxel in participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Depending on the Cohort you are assigned to, you may be asked to perform assessments, fill out questionnaires, etc.
Requirements for healthy volunteers are different than for those with a specific condition. If you are interested in becoming a healthy volunteer for this study, use the below categories to determine if you are able to participate.
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Sid Sheth
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Head and Neck)
24-0434
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
